COVID-19 und chronisch-entzündliche Darmerkrankungen

The coronavirus disease 2019 (COVID-19) pandemic continues to impact the lives of patients with inflammatory bowel disease (IBD). Extensive investigations over the past 3 years have shown that the vast majority of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections and COVID-19 diseases in IBD patients are mild. The disease activity of IBD is usually not influenced, but some patients may experience temporary gastrointestinal symptoms. With the exception of systemic glucocorticoids, commonly used immunomodulatory drugs had no influence on the severity of COVID-19 disease and the overall mortality did not differ from the general population. However, vaccine response is decreased in a substance-dependent manner. In this review, we summarize the most important, practice-relevant studies.